rethinkPeptides Search
Menu
Study breakdown

A Blood Pressure-Lowering Peptide Identified from Velvet Antler Shows Potent ACE Inhibition

In Vitro + Animal StudyLow evidence
The takeaway

A five-amino-acid peptide isolated from velvet antler potently inhibited the blood pressure enzyme ACE at very low concentrations and significantly reduced blood pressure when given orally to hypertensive rats.

IC50 = 3.72 μM

The velvet antler pentapeptide inhibited ACE at a concentration of just 3.72 micromolar — indicating very potent enzyme-blocking activity for a food-derived peptide.

What the researchers found

Researchers isolated a specific five-amino-acid peptide (Asp-Asn-Arg-Tyr-Tyr, molecular weight 730.31 Da) from enzymatic digestion of velvet antler that powerfully inhibits angiotensin I-converting enzyme (ACE), a key enzyme in blood pressure regulation. The peptide showed an IC50 value of 3.72 μM against ACE — indicating potent inhibitory activity at very low concentrations. Molecular docking analysis confirmed stable binding between the peptide and ACE at multiple active-site residues. When given orally to spontaneously hypertensive rats, the peptide significantly reduced blood pressure.

Why it matters

ACE inhibitors are among the most widely prescribed blood pressure medications, but current drugs are synthetic pharmaceuticals with side effects like chronic cough. Food-derived peptides that naturally inhibit ACE represent a potential alternative — functional food ingredients that could help manage blood pressure with fewer side effects. Identifying the exact structure and mechanism of these peptides, as this study does, is a critical step toward developing them as practical nutraceuticals.

The numbers in context

Pentapeptide MW 730.31 Da · IC50 = 3.72 μM against ACE · Sequence: Asp-Asn-Arg-Tyr-Tyr

How the study worked

The peptide was purified from alcalase hydrolysate of velvet antler (deer antler in its growth stage). Its structure was determined by quadrupole time-of-flight electrospray ionization mass spectroscopy. ACE inhibition was measured using enzyme reaction assays. In silico molecular docking analysis modeled how the peptide binds to ACE. The antihypertensive effect was tested in vivo by oral administration to spontaneously hypertensive rats (SHRs), a standard animal model for hypertension research.

Who was studied

In vitro enzyme assays and spontaneously hypertensive rats (SHRs); no human subjects

What this study cannot tell us

This study was conducted in vitro and in an animal model — no human data exists for this peptide. The spontaneously hypertensive rat is a useful but imperfect model for human hypertension. The study doesn't address whether the peptide survives gastrointestinal digestion intact in humans, what the optimal dose would be, or whether the blood pressure effects are sustained with chronic use. Velvet antler sourcing also raises sustainability and ethical considerations.

How to read the evidence

This study provides solid in vitro evidence of ACE inhibition with structural characterization, supported by molecular docking and an animal model. However, it remains preclinical — no human studies have been conducted, and oral bioavailability in humans is unknown.

When this study was published

Published in 2023, this is a recent study in the active field of food-derived bioactive peptides. The findings are consistent with similar research on ACE-inhibitory peptides from other protein sources.

The bigger picture

Food-derived ACE-inhibitory peptides are a growing area of nutraceutical research, with candidates sourced from milk, fish, soybeans, and other proteins. Velvet antler adds another source to this list. The broader goal is identifying natural peptides that could help manage blood pressure either as functional foods or dietary supplements, potentially complementing or reducing the need for pharmaceutical ACE inhibitors in mild hypertension. However, the gap between animal studies and proven human efficacy remains substantial.

Questions still open

  • Does this pentapeptide survive human gastrointestinal digestion intact, or is it broken down before it can reach the bloodstream and inhibit ACE?
  • How does the blood pressure-lowering potency compare to pharmaceutical ACE inhibitors at equivalent doses in human studies?
  • Could this peptide be synthesized or produced at scale without relying on velvet antler as a source material?

Common questions

What is ACE and why does inhibiting it lower blood pressure?
ACE (angiotensin I-converting enzyme) converts a hormone called angiotensin I into angiotensin II, which constricts blood vessels and raises blood pressure. Blocking ACE prevents this conversion, allowing blood vessels to relax and blood pressure to drop. Many common blood pressure medications (like lisinopril and enalapril) work this way.
Can eating velvet antler lower blood pressure?
This study isolated a specific peptide from enzymatically digested velvet antler that lowered blood pressure in rats. However, eating velvet antler directly would not deliver this specific peptide — it requires enzymatic processing to release it from the parent protein. No human studies have been conducted.

Read the original research

Structure Characterization and Antihypertensive Effect of an Antioxidant Peptide Purified from Alcalase Hydrolysate of Velvet Antler.

Food science of animal resources, 43(1), 184-194

Citation

Im, Seung Tae; Lee, Seung-Hong. (2023). Structure Characterization and Antihypertensive Effect of an Antioxidant Peptide Purified from Alcalase Hydrolysate of Velvet Antler.. Food science of animal resources, 43(1), 184-194. https://doi.org/10.5851/kosfa.2022.e70